Loading…
Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial
Background Urticaria is a distressing condition associated with diverse clinical presentations. Chronic spontaneous urticaria (CsU) is characterized by wheals and angioedema. Its treatment requires an algorithmic approach to identify the optimum medication. Objectives Cetirizine is commonly used in...
Saved in:
| Published in: | International journal of dermatology 2014-05, Vol.53 (5), p.643-649 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093 |
| container_end_page | 649 |
| container_issue | 5 |
| container_start_page | 643 |
| container_title | International journal of dermatology |
| container_volume | 53 |
| creator | Dakhale, Ganesh N. Shinde, Abhijit T. Mahatme, Mohini S. Hiware, Sachin K. Mishra, Dharmendra B. Mukhi, Jayesh I. Salve, Anoop M. |
| description | Background
Urticaria is a distressing condition associated with diverse clinical presentations. Chronic spontaneous urticaria (CsU) is characterized by wheals and angioedema. Its treatment requires an algorithmic approach to identify the optimum medication.
Objectives
Cetirizine is commonly used in the treatment of urticaria. Rupatadine is a selective non‐sedating H1‐antihistamine approved for the treatment of CsU. This trial was conducted to ascertain whether the properties of rupatadine offer advantages over cetirizine.
Methods
Seventy patients with CsU were enrolled. Parameters assessed included: (i) mean number of wheals (MNW); (ii) pruritus; (iii) mean total symptom score (MTSS); (iv) size of wheal; (v) interference of wheals with sleep; and (vi) sedation. Patients with CsU were divided randomly into two groups. Routine investigations were performed at baseline and at the end of the study.
Results
Evaluations of MTSS, MNW, and pruritus revealed statistically significant differences at week 3 compared with baseline in the cetirizine group. However, greater reductions in these parameters were obtained with rupatadine. In patients receiving rupatadine, reductions in the MNW, size of wheals, and intensity of erythema were also significant at six weeks (P |
| doi_str_mv | 10.1111/ijd.12250 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1519262260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1519262260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093</originalsourceid><addsrcrecordid>eNp1kE1P3DAQhq2KqixLD_wB5COVCPgjtje9VQvd8iHgAOrRcuyJasgmi-1Al9_Aj8Y0wK1zGY31zDPWi9AOJQc016G_dQeUMUE-oQnlUhSl5GwDTQihtKiIqDbRVoy3eeSMll_QJis5I4rNJuh53vrOW9NiaBqwyT9ABzFi0zkcTQNpjfsGW0g--CffAX6AEIeIw7AyybjXF99h-yf02YLjqu-S6aDPxBBS9gZvvmODQ_b1S_8Ebh-7fqhbKOp8OE-yeAS4wymD7Tb63Jg2wte3PkU3P4-v57-K88vFyfzHeWG55KRQCkAJZZ0UouYNMzNV0bIWdakoNxWU3DnOGweVm7GSlDADyZ2VllS1kaTiU7Q3elehvx8gJr300ULbjl_XVNCKScYkyei3EbWhjzFAo1fBL01Ya0r0a_g6h6__hZ_Z3TftUC_BfZDvaWfgcAQefQvr_5v0yenRu7IYN3xM8Pdjw4Q7LRVXQv--WOjTi6szRc6u9Zy_AMvNn08</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1519262260</pqid></control><display><type>article</type><title>Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Dakhale, Ganesh N. ; Shinde, Abhijit T. ; Mahatme, Mohini S. ; Hiware, Sachin K. ; Mishra, Dharmendra B. ; Mukhi, Jayesh I. ; Salve, Anoop M.</creator><creatorcontrib>Dakhale, Ganesh N. ; Shinde, Abhijit T. ; Mahatme, Mohini S. ; Hiware, Sachin K. ; Mishra, Dharmendra B. ; Mukhi, Jayesh I. ; Salve, Anoop M.</creatorcontrib><description>Background
Urticaria is a distressing condition associated with diverse clinical presentations. Chronic spontaneous urticaria (CsU) is characterized by wheals and angioedema. Its treatment requires an algorithmic approach to identify the optimum medication.
Objectives
Cetirizine is commonly used in the treatment of urticaria. Rupatadine is a selective non‐sedating H1‐antihistamine approved for the treatment of CsU. This trial was conducted to ascertain whether the properties of rupatadine offer advantages over cetirizine.
Methods
Seventy patients with CsU were enrolled. Parameters assessed included: (i) mean number of wheals (MNW); (ii) pruritus; (iii) mean total symptom score (MTSS); (iv) size of wheal; (v) interference of wheals with sleep; and (vi) sedation. Patients with CsU were divided randomly into two groups. Routine investigations were performed at baseline and at the end of the study.
Results
Evaluations of MTSS, MNW, and pruritus revealed statistically significant differences at week 3 compared with baseline in the cetirizine group. However, greater reductions in these parameters were obtained with rupatadine. In patients receiving rupatadine, reductions in the MNW, size of wheals, and intensity of erythema were also significant at six weeks (P < 0.001) and were significantly greater than those in the cetirizine group (P < 0.05).
Conclusions
Improvements in MTSS, MNW, size of wheals, intensity of erythema, and differential eosinophil count imply that rupatadine is a particularly attractive therapeutic modality compared with cetirizine for the treatment of CsU.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.12250</identifier><identifier>PMID: 24320728</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Cetirizine - adverse effects ; Cetirizine - therapeutic use ; Chronic Disease ; Cyproheptadine - adverse effects ; Cyproheptadine - analogs & derivatives ; Cyproheptadine - therapeutic use ; Double-Blind Method ; Female ; Histamine H1 Antagonists, Non-Sedating - adverse effects ; Histamine H1 Antagonists, Non-Sedating - therapeutic use ; Humans ; Male ; Prospective Studies ; Urticaria - drug therapy</subject><ispartof>International journal of dermatology, 2014-05, Vol.53 (5), p.643-649</ispartof><rights>2013 The International Society of Dermatology</rights><rights>2013 The International Society of Dermatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093</citedby><cites>FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24320728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dakhale, Ganesh N.</creatorcontrib><creatorcontrib>Shinde, Abhijit T.</creatorcontrib><creatorcontrib>Mahatme, Mohini S.</creatorcontrib><creatorcontrib>Hiware, Sachin K.</creatorcontrib><creatorcontrib>Mishra, Dharmendra B.</creatorcontrib><creatorcontrib>Mukhi, Jayesh I.</creatorcontrib><creatorcontrib>Salve, Anoop M.</creatorcontrib><title>Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Background
Urticaria is a distressing condition associated with diverse clinical presentations. Chronic spontaneous urticaria (CsU) is characterized by wheals and angioedema. Its treatment requires an algorithmic approach to identify the optimum medication.
Objectives
Cetirizine is commonly used in the treatment of urticaria. Rupatadine is a selective non‐sedating H1‐antihistamine approved for the treatment of CsU. This trial was conducted to ascertain whether the properties of rupatadine offer advantages over cetirizine.
Methods
Seventy patients with CsU were enrolled. Parameters assessed included: (i) mean number of wheals (MNW); (ii) pruritus; (iii) mean total symptom score (MTSS); (iv) size of wheal; (v) interference of wheals with sleep; and (vi) sedation. Patients with CsU were divided randomly into two groups. Routine investigations were performed at baseline and at the end of the study.
Results
Evaluations of MTSS, MNW, and pruritus revealed statistically significant differences at week 3 compared with baseline in the cetirizine group. However, greater reductions in these parameters were obtained with rupatadine. In patients receiving rupatadine, reductions in the MNW, size of wheals, and intensity of erythema were also significant at six weeks (P < 0.001) and were significantly greater than those in the cetirizine group (P < 0.05).
Conclusions
Improvements in MTSS, MNW, size of wheals, intensity of erythema, and differential eosinophil count imply that rupatadine is a particularly attractive therapeutic modality compared with cetirizine for the treatment of CsU.</description><subject>Adult</subject><subject>Cetirizine - adverse effects</subject><subject>Cetirizine - therapeutic use</subject><subject>Chronic Disease</subject><subject>Cyproheptadine - adverse effects</subject><subject>Cyproheptadine - analogs & derivatives</subject><subject>Cyproheptadine - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Histamine H1 Antagonists, Non-Sedating - adverse effects</subject><subject>Histamine H1 Antagonists, Non-Sedating - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Prospective Studies</subject><subject>Urticaria - drug therapy</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kE1P3DAQhq2KqixLD_wB5COVCPgjtje9VQvd8iHgAOrRcuyJasgmi-1Al9_Aj8Y0wK1zGY31zDPWi9AOJQc016G_dQeUMUE-oQnlUhSl5GwDTQihtKiIqDbRVoy3eeSMll_QJis5I4rNJuh53vrOW9NiaBqwyT9ABzFi0zkcTQNpjfsGW0g--CffAX6AEIeIw7AyybjXF99h-yf02YLjqu-S6aDPxBBS9gZvvmODQ_b1S_8Ebh-7fqhbKOp8OE-yeAS4wymD7Tb63Jg2wte3PkU3P4-v57-K88vFyfzHeWG55KRQCkAJZZ0UouYNMzNV0bIWdakoNxWU3DnOGweVm7GSlDADyZ2VllS1kaTiU7Q3elehvx8gJr300ULbjl_XVNCKScYkyei3EbWhjzFAo1fBL01Ya0r0a_g6h6__hZ_Z3TftUC_BfZDvaWfgcAQefQvr_5v0yenRu7IYN3xM8Pdjw4Q7LRVXQv--WOjTi6szRc6u9Zy_AMvNn08</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Dakhale, Ganesh N.</creator><creator>Shinde, Abhijit T.</creator><creator>Mahatme, Mohini S.</creator><creator>Hiware, Sachin K.</creator><creator>Mishra, Dharmendra B.</creator><creator>Mukhi, Jayesh I.</creator><creator>Salve, Anoop M.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial</title><author>Dakhale, Ganesh N. ; Shinde, Abhijit T. ; Mahatme, Mohini S. ; Hiware, Sachin K. ; Mishra, Dharmendra B. ; Mukhi, Jayesh I. ; Salve, Anoop M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Cetirizine - adverse effects</topic><topic>Cetirizine - therapeutic use</topic><topic>Chronic Disease</topic><topic>Cyproheptadine - adverse effects</topic><topic>Cyproheptadine - analogs & derivatives</topic><topic>Cyproheptadine - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Histamine H1 Antagonists, Non-Sedating - adverse effects</topic><topic>Histamine H1 Antagonists, Non-Sedating - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Prospective Studies</topic><topic>Urticaria - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dakhale, Ganesh N.</creatorcontrib><creatorcontrib>Shinde, Abhijit T.</creatorcontrib><creatorcontrib>Mahatme, Mohini S.</creatorcontrib><creatorcontrib>Hiware, Sachin K.</creatorcontrib><creatorcontrib>Mishra, Dharmendra B.</creatorcontrib><creatorcontrib>Mukhi, Jayesh I.</creatorcontrib><creatorcontrib>Salve, Anoop M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dakhale, Ganesh N.</au><au>Shinde, Abhijit T.</au><au>Mahatme, Mohini S.</au><au>Hiware, Sachin K.</au><au>Mishra, Dharmendra B.</au><au>Mukhi, Jayesh I.</au><au>Salve, Anoop M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2014-05</date><risdate>2014</risdate><volume>53</volume><issue>5</issue><spage>643</spage><epage>649</epage><pages>643-649</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><abstract>Background
Urticaria is a distressing condition associated with diverse clinical presentations. Chronic spontaneous urticaria (CsU) is characterized by wheals and angioedema. Its treatment requires an algorithmic approach to identify the optimum medication.
Objectives
Cetirizine is commonly used in the treatment of urticaria. Rupatadine is a selective non‐sedating H1‐antihistamine approved for the treatment of CsU. This trial was conducted to ascertain whether the properties of rupatadine offer advantages over cetirizine.
Methods
Seventy patients with CsU were enrolled. Parameters assessed included: (i) mean number of wheals (MNW); (ii) pruritus; (iii) mean total symptom score (MTSS); (iv) size of wheal; (v) interference of wheals with sleep; and (vi) sedation. Patients with CsU were divided randomly into two groups. Routine investigations were performed at baseline and at the end of the study.
Results
Evaluations of MTSS, MNW, and pruritus revealed statistically significant differences at week 3 compared with baseline in the cetirizine group. However, greater reductions in these parameters were obtained with rupatadine. In patients receiving rupatadine, reductions in the MNW, size of wheals, and intensity of erythema were also significant at six weeks (P < 0.001) and were significantly greater than those in the cetirizine group (P < 0.05).
Conclusions
Improvements in MTSS, MNW, size of wheals, intensity of erythema, and differential eosinophil count imply that rupatadine is a particularly attractive therapeutic modality compared with cetirizine for the treatment of CsU.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24320728</pmid><doi>10.1111/ijd.12250</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-9059 |
| ispartof | International journal of dermatology, 2014-05, Vol.53 (5), p.643-649 |
| issn | 0011-9059 1365-4632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1519262260 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Cetirizine - adverse effects Cetirizine - therapeutic use Chronic Disease Cyproheptadine - adverse effects Cyproheptadine - analogs & derivatives Cyproheptadine - therapeutic use Double-Blind Method Female Histamine H1 Antagonists, Non-Sedating - adverse effects Histamine H1 Antagonists, Non-Sedating - therapeutic use Humans Male Prospective Studies Urticaria - drug therapy |
| title | Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T05%3A12%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20effectiveness%20and%20safety%20of%20cetirizine%20versus%20rupatadine%20in%20chronic%20spontaneous%20urticaria:%20a%20randomized,%20double-blind,%206-week%20trial&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Dakhale,%20Ganesh%20N.&rft.date=2014-05&rft.volume=53&rft.issue=5&rft.spage=643&rft.epage=649&rft.pages=643-649&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.12250&rft_dat=%3Cproquest_cross%3E1519262260%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3630-77ee757cd655b3f2a87914b5b4713a9e43dd33fde9d82404e8e63dc6c09ba6093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1519262260&rft_id=info:pmid/24320728&rfr_iscdi=true |